Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Successes and failures of stem cell transplantation in autoimmune diseases
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 1193933
Author(s) Tyndall, Alan
Author(s) at UniBasel De Vere-Tyndall, Alan
Year 2011
Title Successes and failures of stem cell transplantation in autoimmune diseases
Journal Hematology / American Society of Hematology education program book
Volume 2011
Pages / Article-Number 280-4
Abstract Over the past 15 years, more than 1500 patients have received HSCT, mostly autologous, as treatment for a severe autoimmune disease (AD). More than 1000 of these have been registered in the European Group for Bone Marrow Transplantation (EBMT) and European League Against Rheumatism (EULAR) combined database. A recent retrospective analysis of 900 patients showed that the majority had multiple sclerosis (MS; n = 345) followed by systemic sclerosis (SSc; n = 175), systemic lupus erythematosus (SLE; n = 85), rheumatoid arthritis (RA; n = 89), juvenile idiopathic arthritis (JIA; n = 65), and idiopathic cytopenic purpura (ITP; n = 37). An overall 85% 5-year survival and 43% progression-free survival was seen, with 100-day transplantation-related mortality (TRM) ranging between 1% (RA) and 11% (SLE and JIA). Approximately 30% of patients in all disease subgroups had a complete response, often durable despite full immune reconstitution. In many patients, such as in those with SSc, morphological improvement such as reduction of skin collagen and normalization of microvasculature was documented beyond any predicted known effects of intense immunosuppression alone. The high TRM was in part related to conditioning intensity, comorbidity, and age, but until the results of the 3 prospective randomized trials are known, an evidence-based modification of the conditioning regimen will not be possible.(1) In recent years, multipotent mesenchymal stromal cells (MSCs) have been tested in various AD, exploiting their immune-modulating properties and apparent low acute toxicity. Despite encouraging small phase 1/2 studies, no positive data from randomized, prospective studies are as yet available in the peer-reviewed literature.
Publisher Society
edoc-URL http://edoc.unibas.ch/dok/A6004169
Full Text on edoc No
Digital Object Identifier DOI 10.1182/asheducation-2011.1.280
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/22160046
Document type (ISI) Journal Article, Review
 
   
Showing record 1 (of 156)


MCSS v5.8 PRO. 0.322 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
06/06/2024